Register for our free email digests:
Latest From Eddingpharm International Holdings Ltd.
Sanofi is the latest big pharma, following on from Merck & Co., AbbVie and others, to team up with Belgian Nanobody drug developer Ablynx.
China is aggressively driving up life sciences innovations, leading the charge in technologies including gene editing and genome testing, prompting executives to take a fresh approach.
Merck could pay up to $167m to try a new epigenetic target, which would build on its existing HDAC inhibitor. Meanwhile, Celgene buys epigenetics-focused Acetylon, which will spin out new company Regenacy to work with its lead HDAC6 inhibitor outside of oncology.
Partnership with France’s Enterome will add a microbiome aspect to Bristol’s immuno-oncology efforts, while its license of Japanese firm Nitto Denko’s siRNA technology could bolster NASH combo therapy development. Meanwhile, Eagle moves into biosimilars with the purchase of Arsia for up to $78m.
- Surgical Equipment & Devices
- Therapeutic Areas
- Neurology, Nervous System
- North America
- Parent & Subsidiaries
- MindFrame Inc.
- Senior Management
Kenneth Charhut, Pres. & CEO
Joshua Benjamin, R&D Mgr.
John Hardin, VP, Global Sales & Mktg.
Thomas J McCarthy, VP, Clin. Affairs & Bus Dev.
- Contact Info
Phone: (949) 204-0800
Irvine, CA 92618
You must sign in to use this functionality
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.